Overview

* Gyre Q2 revenue of $26.8 mln missed analyst expectations, per LSEG data

* Net income for Q2 was $1.6 mln, compared to $4.5 mln last year

* Company reaffirmed full-year revenue guidance of $118-128 mln

* Ping Zhang appointed interim CEO as Dr. Han Ying transitions to scientific role

Outlook

* Gyre reaffirms 2025 revenue guidance of $118-128 mln

Result Drivers

* NEW PRODUCT LAUNCHES - Revenue increase driven by launch of Etorel and Contiva, contributing $1.6 mln and $1.5 mln respectively

* ETUARY DECLINE - Sales of ETUARY decreased due to weaker economic conditions and increased competition in the IPF market

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $26.77 $30.80

Revenue mln mln (1

Analyst)

Q2 Net $1.58

Income mln

Q2 $2.17

Operatin mln

g Profit

Q2 $2.24

Pretax mln

Profit

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Gyre Therapeutics Inc ( GYRE ) is $20.00, about 64.1% above its August 8 closing price of $7.19

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)